HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Effects of cepharanthin on leukopenia and thrombocytopenia caused by CDDP-ACR-CPA therapy of ovarian cancer].

Abstract
Effects of cepharanthin (50 mg/day, i.v.) an alkaloid of bis-coclaurin type, were studied on leucopenia and thrombocytopenia caused by CDDP-ACR-CPA (CAP) therapy against ovarian cancer. The study was carried out with 44 therapy courses on 17 patients of ovarian cancer receiving CAP administration. Nineteen of the 44 courescin loaded cepharanthin. The minimum number of leucocytes was found on 15.2 +/- 4.4 and 17.2 +/- 2.1 days after CAP-administration with and without cepharanthin, respectively. Leucocyte count 21 days after CAP-administration compared to that before the administration were 90.1 and 56.8% in cepharanthin and non-cepharanthin groups, respectively, which indicate a significant difference (p less than 0.05). As to the platelet count, cepharanthin group also showed attendant toward earlier recovery of thrombocytopenia than non-cepharanthin group. We conclude that the administration of cepharanthin during CAP therapy promotes the recovery from leucopenia and thrombocytopenia.
AuthorsN Ushiki, T Jobo, T Shimoda, H Kuramoto, M Arai
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 15 Issue 9 Pg. 2701-6 (Sep 1988) ISSN: 0385-0684 [Print] Japan
PMID3415268 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Alkaloids
  • Benzylisoquinolines
  • cepharanthine
  • Doxorubicin
  • Cyclophosphamide
  • Peptichemio
Topics
  • Adult
  • Aged
  • Alkaloids (therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Benzylisoquinolines
  • Cyclophosphamide (administration & dosage, adverse effects)
  • Doxorubicin (administration & dosage, adverse effects)
  • Drug Administration Schedule
  • Female
  • Humans
  • Leukopenia (drug therapy)
  • Middle Aged
  • Ovarian Neoplasms (blood, drug therapy)
  • Peptichemio (administration & dosage, adverse effects)
  • Thrombocytopenia (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: